BUZZ-Immix因被美国食品及药物管理局授予血液病疗法 "突破性 "标签而攀升

路透中文

Jan 28

BUZZ-Immix因被<a href="https://laohu8.com/S/USFD">美国食品</a>及药物管理局授予血液病疗法 "突破性 "标签而攀升

1月28日 - ** Immix生物制药公司IMMX.O股价盘前上涨4.4%至6.20美元

** 该公司称，美国食品及药物管理局已授予NXC-201 "突破性疗法 "称号，用于治疗AL淀粉样变性（一种血液疾病）。

** "突破性疗法 "标签旨在加快开发和审查治疗严重疾病或未满足医疗需求的药物

** 称该标签是基于 NXC-201 的中期试验结果

** 公司计划今年提交该疗法的上市申请

** AL淀粉样变性是一种罕见的严重血液相关疾病，异常蛋白质会在重要器官中堆积，干扰器官功能

** 截至上次收盘，公司股价在过去 12 个月中上涨了两倍多

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2606712343"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2606712343\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2606712343?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-01-28 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606712343","market":"hk","top_or_hot":-1,"title":"BUZZ-Immix因被美国食品及药物管理局授予血液病疗法 \"突破性 \"标签而攀升","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Immix因被<a href=\"https://laohu8.com/S/USFD\">美国食品</a>及药物管理局授予血液病疗法 \"突破性 \"标签而攀升</title></head><body><p><span>1月28日</span><span> - </span>** Immix生物制药公司<span>IMMX.O</span>股价盘前上涨4.4%至6.20美元</p><p>** 该公司称，美国食品及药物管理局已授予NXC-201 \"突破性疗法 \"称号，用于治疗AL淀粉样变性（一种血液疾病）。</p><p>** \"突破性疗法 \"标签旨在加快开发和审查治疗严重疾病或未满足医疗需求的药物</p><p>** 称该标签是基于 NXC-201 的中期试验结果 </p><p>** 公司计划今年提交该疗法的上市申请</p><p>** AL淀粉样变性是一种罕见的严重血液相关疾病，异常蛋白质会在重要器官中堆积，干扰器官功能</p><p>** 截至上次收盘，公司股价在过去 12 个月中上涨了两倍多</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Immix因被美国食品及药物管理局授予血液病疗法 \"突破性 \"标签而攀升</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Immix因被美国食品及药物管理局授予血液病疗法 \"突破性 \"标签而攀升\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-01-28 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Immix因被<a href=\"https://laohu8.com/S/USFD\">美国食品</a>及药物管理局授予血液病疗法 \"突破性 \"标签而攀升</title></head><body><p><span>1月28日</span><span> - </span>** Immix生物制药公司<span>IMMX.O</span>股价盘前上涨4.4%至6.20美元</p><p>** 该公司称，美国食品及药物管理局已授予NXC-201 \"突破性疗法 \"称号，用于治疗AL淀粉样变性（一种血液疾病）。</p><p>** \"突破性疗法 \"标签旨在加快开发和审查治疗严重疾病或未满足医疗需求的药物</p><p>** 称该标签是基于 NXC-201 的中期试验结果 </p><p>** 公司计划今年提交该疗法的上市申请</p><p>** AL淀粉样变性是一种罕见的严重血液相关疾病，异常蛋白质会在重要器官中堆积，干扰器官功能</p><p>** 截至上次收盘，公司股价在过去 12 个月中上涨了两倍多</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMMX","symbol_name":"Immix Biopharma, Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nL4S3YT1LB:1","article_id":"2606712343","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2606712343","pubTimestamp":1769608905,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Immix因被美国食品及药物管理局授予血液病疗法 \"突破性 \"标签而攀升1月28日 - ** Immix生物制药公司IMMX.O股价盘前上涨4.4%至6.20美元** 该公司称，美国食品及药物管理局已授予NXC-201 \"突破性疗法 \"称号，用于治疗AL淀粉样变性。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IMMX":"Immix Biopharma, Inc","BK4139":"生物科技"},"translate_title":"BUZZ-Immix climbs after being awarded \"breakthrough\" label for hematological disease therapy by the US Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMMX":0.9},"content_text":"BUZZ-Immix因被美国食品及药物管理局授予血液病疗法 \"突破性 \"标签而攀升1月28日 - ** Immix生物制药公司IMMX.O股价盘前上涨4.4%至6.20美元** 该公司称，美国食品及药物管理局已授予NXC-201 \"突破性疗法 \"称号，用于治疗AL淀粉样变性（一种血液疾病）。** \"突破性疗法 \"标签旨在加快开发和审查治疗严重疾病或未满足医疗需求的药物** 称该标签是基于 NXC-201 的中期试验结果 ** 公司计划今年提交该疗法的上市申请** AL淀粉样变性是一种罕见的严重血液相关疾病，异常蛋白质会在重要器官中堆积，干扰器官功能** 截至上次收盘，公司股价在过去 12 个月中上涨了两倍多(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}